Cimzia and Pregnancy, Breastfeeding, and More

Medical note: This article is for educational purposes only and should not replace medical advice from your rheumatologist, gastroenterologist, dermatologist, obstetrician, pediatrician, or pharmacist. Do not start, stop, delay, or change Cimzia without your healthcare team’s guidance.

Introduction: When Treatment Plans Meet Baby Plans

Pregnancy already comes with enough planning: prenatal vitamins, appointment calendars, snack emergencies, and the mysterious ability to cry at a commercial for paper towels. Add a chronic inflammatory condition into the mix, and the planning gets more serious. If you take Cimzia, also known by its generic name certolizumab pegol, you may wonder whether it can be used during pregnancy, whether it passes into breast milk, whether it affects fertility, and what it means for your baby’s vaccines after birth.

Cimzia is a biologic medicine called a tumor necrosis factor blocker, often shortened to TNF blocker or anti-TNF therapy. It is used for several inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis in certain pediatric patients. In plain English, Cimzia helps calm an overactive immune response that can drive pain, swelling, gut inflammation, skin plaques, and fatigue.

The big question is not simply, “Is Cimzia safe in pregnancy?” A better question is, “What is the safest overall plan for the parent and baby?” Sometimes stopping inflammation treatment can be riskier than continuing it. Active rheumatoid arthritis or Crohn’s disease, for example, has been linked with higher risks such as preterm birth, low birth weight, fetal loss, and babies being small for gestational age. That is why the decision should be individualized, calm, and guided by clinicians who understand both your disease and your pregnancy goals.

What Is Cimzia?

Cimzia is the brand name for certolizumab pegol. It works by binding to TNF-alpha, a protein involved in inflammation. When TNF-alpha is too active, it can contribute to autoimmune and inflammatory disease activity. By blocking TNF-alpha, Cimzia may reduce symptoms and help maintain disease control.

One feature makes Cimzia especially important in pregnancy discussions: it does not contain an Fc region. Many antibody-based biologics contain an Fc portion, which can help them cross the placenta more actively, especially later in pregnancy. Cimzia’s structure is different, and research has shown minimal to no placental transfer in most studied infants. That does not mean it is magically risk-freeno medication earns a superhero cape that easilybut it does help explain why many specialists view Cimzia differently from some other TNF blockers during pregnancy.

Cimzia and Pregnancy: What the Evidence Suggests

Placental Transfer Appears Low

Pregnancy studies measuring certolizumab pegol levels in mothers, umbilical cord blood, and infant blood have found little to no transfer across the placenta in most cases. In one well-known pharmacokinetic study, most infants had no measurable Cimzia levels at birth, even though their mothers used the medication in the third trimester. This matters because the third trimester is usually when many antibody-based biologics cross the placenta most actively.

Current prescribing information notes that available registry data are limited and not enough to fully determine the risk of major birth defects or other adverse pregnancy outcomes. However, it also states that placental transfer was negligible in most infants and low in others. In short, the information is reassuring, but not a blank check. Medicine loves nuance, even when patients would prefer a giant green “approved” sticker.

Why Disease Control Matters During Pregnancy

For people with inflammatory diseases, stable disease before conception is often one of the best gifts you can give your future pregnancy. Inflammatory bowel disease experts commonly recommend being in remission for several months before trying to conceive when possible. Rheumatology guidance also emphasizes pregnancy planning during periods of low disease activity and while using pregnancy-compatible medications.

That matters because a flare during pregnancy is not just uncomfortable. Active disease can increase the chance of complications. For Crohn’s disease, uncontrolled inflammation may affect nutrition, weight gain, and pregnancy outcomes. For rheumatoid arthritis or axial spondyloarthritis, severe inflammation and pain can affect sleep, mobility, stress levels, and the ability to stay active. For psoriasis or psoriatic arthritis, flares can be physically and emotionally draining. The goal is not to take medication “just because.” The goal is to keep the parent well enough for pregnancy to proceed as smoothly as possible.

Should Cimzia Be Continued During Pregnancy?

Many specialists consider Cimzia one of the more pregnancy-compatible biologic options when a TNF blocker is needed. The American College of Rheumatology has strongly recommended continuation of certolizumab before and during pregnancy for patients with rheumatic and musculoskeletal diseases when clinically appropriate. That recommendation is partly based on Cimzia’s minimal placental transfer.

Still, your exact plan depends on your diagnosis, disease severity, medication history, pregnancy stage, infection risk, and whether you have had recent flares. Some people may continue Cimzia throughout pregnancy. Others may adjust timing, especially around delivery, if their healthcare team has a specific reason. What you should not do is suddenly stop Cimzia because of a positive pregnancy test without speaking to your clinician. Stopping abruptly may invite a flare at exactly the moment your body is already running the world’s most complicated construction project.

Cimzia, Birth Defects, and Miscarriage Risk

Every pregnancy has a background risk of birth defects and miscarriage, whether or not medications are used. In the general U.S. population, major birth defects occur in a small percentage of clinically recognized pregnancies, and miscarriage is also relatively common. Available Cimzia data have not shown a clear signal of increased major birth defects, but the data are not large enough to prove there is no risk at all.

That is why pregnancy exposure registries matter. They collect real-world information from people who used certain medications during pregnancy. If you are taking Cimzia and become pregnant, your healthcare provider may mention pregnancy registry participation. It is not required, but it helps researchers better understand medication outcomes over time. Think of it as contributing one puzzle piece to a much larger medical picture.

Cimzia and Breastfeeding

Does Cimzia Pass Into Breast Milk?

Studies measuring Cimzia in breast milk have found very low or undetectable levels. In a study of 17 lactating women, many breast milk samples had no measurable certolizumab pegol, and no serious adverse reactions were reported in the breastfed infants in that study. Lactation references generally describe certolizumab as low risk for nursing infants because only small amounts appear in milk and the drug is a large protein that is likely broken down in the infant’s digestive tract.

This is one reason many healthcare professionals consider Cimzia compatible with breastfeeding when the parent needs it for disease control. However, there are a few extra considerations. Premature babies and newborns younger than one month may have less mature digestive systems, so your pediatrician may want to be especially involved in the conversation. Also, breastfeeding decisions should include the benefits of breast milk, the parent’s need for treatment, the risks of untreated disease, and any infant-specific medical concerns.

Do You Need to “Pump and Dump”?

For Cimzia, routine “pump and dump” is generally not supported by current evidence. The medication level in milk is low, and timing breastfeeding around injections is usually not necessary unless your healthcare team gives you a specific reason. That is good news, because new parents already have enough logistics. Nobody needs a spreadsheet titled “Milk Timing vs. Biologic Injection vs. Baby Screaming at 2:13 a.m.” unless absolutely necessary.

Cimzia and Fertility

There is no strong evidence that Cimzia reduces fertility in women or men. In fact, controlling inflammation may support overall reproductive health for some people because active autoimmune or inflammatory disease can interfere with energy, nutrition, sexual health, and pregnancy planning. For men or sperm-producing partners, expert guidance generally considers TNF inhibitors compatible with attempts to conceive.

That said, fertility is influenced by many factors: age, disease activity, menstrual regularity, sperm health, other medications, pelvic inflammation, prior surgeries, weight, stress, and conditions such as endometriosis or polycystic ovary syndrome. If pregnancy is not happening after several months of trying, it is reasonable to ask for a fertility evaluation rather than blaming Cimzia automatically.

Cimzia and Birth Control

Cimzia itself is not known to make hormonal birth control less effective. However, pregnancy planning is still important because many people who take Cimzia also take other medications, and some of those may not be pregnancy-compatible. Methotrexate, for example, is not used during pregnancy and must be stopped well before conception under medical supervision. Some people with inflammatory disease also take steroids, NSAIDs, immunomodulators, or other biologics, each with its own pregnancy considerations.

If you are not ready to become pregnant, ask your healthcare provider which birth control methods are safest for you. If you are ready, schedule a preconception visit before trying if possible. Bring your medication list, supplement list, vaccine history, flare history, and a realistic description of how you have been feelingnot the polite “fine” we all say when we are absolutely not fine.

Vaccines, Cimzia, and Your Baby

Vaccines for the Parent

People receiving Cimzia should generally avoid live vaccines during or immediately before treatment. Before starting Cimzia, healthcare providers often review immunizations, including TB screening and hepatitis B considerations where appropriate. During pregnancy, recommended vaccines such as flu, Tdap, COVID-19, and RSV vaccination may be discussed depending on timing, eligibility, and current guidelines.

Vaccines for the Baby

Most vaccines given to infants in the United States during the first year are not live vaccines. The main live vaccine commonly given in early infancy is rotavirus. Because Cimzia appears to have minimal placental transfer, some expert resources treat it differently from other biologics that can produce higher infant drug levels. Still, vaccine decisions for a baby exposed to any biologic during pregnancy should be discussed with the pediatrician. The safest move is simple: tell the baby’s doctor that Cimzia was used during pregnancy and breastfeeding so they can make an informed vaccine plan.

Common Side Effects and Safety Concerns

Cimzia can lower the immune system’s ability to fight infections. Serious infections, including tuberculosis and invasive fungal, bacterial, or viral infections, have been reported with TNF blockers. Your healthcare provider should test for TB before starting Cimzia and monitor for symptoms during treatment. Call your clinician if you develop fever, persistent cough, burning with urination, shortness of breath, painful skin sores, unusual fatigue, or other signs of infection.

Other possible concerns include allergic reactions, hepatitis B reactivation in carriers, worsening heart failure, demyelinating disease, blood disorders, lupus-like symptoms, and certain malignancy warnings. Most people will not experience these severe reactions, but pregnancy is not the time to “wait and see” with serious symptoms. If something feels off, contact your healthcare team.

Questions to Ask Your Doctor Before or During Pregnancy

• Is my disease controlled well enough to try to conceive?
• Should I continue Cimzia through all trimesters?
• Do I need any dose timing changes near delivery?
• Are my other medications pregnancy-compatible?
• Should I join a pregnancy exposure registry?
• What symptoms should make me call right away?
• Can I breastfeed while using Cimzia?
• What should my baby’s pediatrician know about Cimzia exposure?
• Are any live vaccines a concern for me or my baby?

Practical Planning Checklist

Real-World Experiences: What Cimzia Planning Can Feel Like

People managing Cimzia and pregnancy often describe the emotional experience as a mix of relief, worry, and paperwork. The relief comes from learning that Cimzia has low placental transfer compared with many other biologic medicines. The worry comes from the fact that pregnancy turns every decision into a tiny courtroom drama. Can I take this medication? What if I flare? What if I do not flare? What if my baby needs a vaccine? What if my mother-in-law reads one terrifying internet post and sends it to me before breakfast?

One common experience is the “preconception appointment wake-up call.” A person may walk into the visit thinking the main topic is simply whether Cimzia can continue. Then the provider asks about disease activity, last flare, steroid use, vaccines, folic acid, other prescriptions, sleep, nutrition, mental health, and whether there is a high-risk obstetrician involved. It can feel like a lot, but it is actually good care. Pregnancy planning with inflammatory disease is not about one drug. It is about building a safety net before the circus begins.

Another common experience is fear of stopping medication. Some patients have worked hard for years to reach remission or low disease activity. The idea of stopping a biologic can feel like opening the door to a flare that was finally under control. For someone with Crohn’s disease, that might mean diarrhea, abdominal pain, weight loss, and poor appetite. For someone with rheumatoid arthritis, it might mean swollen hands, morning stiffness, and exhaustion. For psoriasis, it may mean plaques returning right when body image is already changing. These are not small concerns, and they deserve to be taken seriously.

Breastfeeding brings a different kind of decision-making. Many new parents want to breastfeed but worry about medicine exposure through milk. Learning that Cimzia levels in breast milk are usually very low or undetectable can be reassuring. Still, the early postpartum period can be intense. A parent may be healing from delivery, learning infant feeding, managing sleep deprivation, and watching for disease symptoms. In that season, the best medication plan is one that is medically sound and realistic. A treatment schedule that looks perfect on paper but collapses at 3 a.m. beside a crying newborn needs adjustment, not guilt.

Parents also often mention the pediatrician conversation. It is easy to assume the baby’s doctor automatically knows every pregnancy medication exposure, but that is not always true. A simple note in the baby’s chart can help: “Parent used Cimzia during pregnancy and may use it while breastfeeding.” This allows the pediatrician to think carefully about vaccines, infections, and any special circumstances such as prematurity. For many families, this conversation is brief and reassuring, but it is still worth having.

The best experience stories usually share one theme: coordinated care. The happiest path is not “I guessed and hoped.” It is “My specialists talked, my OB knew the plan, my pediatrician was informed, and I knew who to call.” Cimzia may be only one piece of the pregnancy puzzle, but when the plan is clear, that piece becomes much less scary.

Conclusion

Cimzia and pregnancy is a topic that deserves both optimism and caution. Current evidence suggests that certolizumab pegol has minimal placental transfer in most studied infants and very low or undetectable levels in breast milk. Many professional recommendations consider Cimzia compatible with pregnancy and breastfeeding when it is needed to control inflammatory disease. At the same time, available pregnancy data are still limited, and every patient’s risks are different.

The most important takeaway is this: do not make the decision alone. If you are pregnant, planning pregnancy, breastfeeding, or thinking about birth control while using Cimzia, talk with your healthcare team early. A well-planned approach can protect disease control, reduce anxiety, and help you move through pregnancy and postpartum life with more confidenceand hopefully fewer late-night internet rabbit holes.